UCB and Sanofi have unveiled a scientific and strategic collaboration to discover and develop novel treatments for immune-mediated diseases in areas such as gastroenterology and arthritis.

The biggest stories of the day delivered to your inbox.

UCB has three products currently in phase III which are due to produce pivotal results in the next few years: brivaracetam for epilepsy, lupus treatment epratuzumab and romosozumab for osteoporosis.

Copyright © 2025 MarketWatch, Inc. All rights reserved.

Discover why a logo is important for your business branding. Get help from a creative logo design agency for impressive results. A company's logo is one of its most valuable assets. More than just a ...

After hours: February 19 at 4:05:05 PM EST ...

Morgan Stanley analyst Sarita Kapila assumed coverage of UCB (UCBJF) with an Equal Weight rating and EUR 200 price target The firm says the hashers are “priced for perfection.” Published first ...

Marketed by Belgian drugmaker UCB (Euronext: UCB), fenfluramine is available immediately for eligible patients under NHS England’s Innovative Medicines Fund designed to deliver faster access for ...

In a report released today, Charles Pitman CFA from Barclays reiterated a Buy rating on UCB SA (0NZT – Research Report), with a price target of €240.00. The company’s shares closed last ...

Speed 4 Mbps beyond 4000GB, Free OTT: Bundled Disney+Hotstar Super Plan ...